

February 13, 2020



# MediPharm Labs Sets Date to Release Full Year 2019 and Fourth Quarter Financial Results

BARRIE, Ontario, Feb. 13, 2020 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm Labs" or the "Company") a global leader in research-driven, pharmaceutical quality cannabis extraction, distillation and derivative product production, announced it will release its audited financial results, within the timelines required by TSX issuers, for the three and twelve months ended December 31, 2019 before markets open on Monday, March 30, 2020.

The Company's management team will also host a conference call and audio webcast on Monday, March 30, 2020 at 8:30 a.m. eastern time to discuss its results and outlook.

## **Conference Call Information:**

Toll-free number: 877-791-0216 / International number: 647-689-5661 / Conference ID: 5576297

Participants are asked to dial in approximately 10 minutes before the start of the call.

## **Audio Webcast:**

An audio webcast will be available in the Events section of the MediPharm Labs' Investor Relations website <https://ir.medipharmlabs.com/news-events> or by visiting the following link:

<https://event.on24.com/wcc/r/2152211/3D5EEC47DD1A08B3183F90AD781074FE>

For those who are unable to participate on the live conference call and webcast, a replay will be available approximately one hour after completion of the call.

## **Replay Information:**

Replay number: 800-585-8367 / International replay number: 416-621-4642 / Conference ID: 5576297

## **About MediPharm Labs**

Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical quality cannabis oil and concentrates and advanced derivative products utilizing a Good

Manufacturing Practices certified facility and ISO standard built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, MediPharm Labs formulates, sensory-tests, processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. As a global leader, MediPharm Labs has completed commercial exports to Australia and is nearing commercialization of its Australian extraction facility. MediPharm Labs Australia was established in 2017.

**For further information, please contact:**

Laura Lepore, VP, Investor Relations  
Telephone: 416-913-7425 ext 1525  
Email: [investors@medipharmlabs.com](mailto:investors@medipharmlabs.com)  
Website: [www.medipharmlabs.com](http://www.medipharmlabs.com)

**CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:**

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, the completion of the Australian facility. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs’ filings, available on the SEDAR website at [www.sedar.com](http://www.sedar.com). There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.



MediPharm Labs

Source: MediPharm Labs Corp.